Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia

MLA

James B. Bussel, et al. “Fostamatinib Is an Effective Second‐line Therapy in Patients with Immune Thrombocytopenia.” British Journal of Haematology, vol. 190, no. 6, July 2020, pp. 933–38. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9386d56a8017c6d25bb456b3db7392d4&authtype=sso&custid=ns315887.

APA

James B. Bussel, Quentin A. Hill, Michelle Sholzberg, Nichola Cooper, Michael D. Tarantino, Sandra Tong, Leslie Todd, Ralph V. Boccia, Michael Boxer, & Waleed Ghanima. (2020). Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia. British Journal of Haematology, 190(6), 933–938.

Chicago

James B. Bussel, Quentin A. Hill, Michelle Sholzberg, Nichola Cooper, Michael D. Tarantino, Sandra Tong, Leslie Todd, Ralph V. Boccia, Michael Boxer, and Waleed Ghanima. 2020. “Fostamatinib Is an Effective Second‐line Therapy in Patients with Immune Thrombocytopenia.” British Journal of Haematology 190 (6): 933–38. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9386d56a8017c6d25bb456b3db7392d4&authtype=sso&custid=ns315887.